8C5 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
LOQTORZI Commercial GrowthLOQTORZI is showing measurable commercial traction, supported by higher sales, new patient starts, and improving treatment duration. Continued quarterly growth would provide a more durable revenue base, strengthen the oncology franchise, and improve operating leverage as adoption expands.
Sustained Cost ReductionThe sustained reduction in R&D and SG&A indicates a leaner operating structure rather than a single-period cost action. Lower recurring expenses can extend financial runway, reduce the revenue needed to support operations, and improve the company’s ability to focus capital on oncology growth and development.
Debt And Liability ImprovementSubstantial debt and legacy-liability reductions simplify the balance sheet and reduce obligations tied to the divested biosimilar business. The new financing structure also extends maturities, giving management more flexibility to fund operations and advance the pipeline while commercial revenues develop.
Bears Say
Severe Cash BurnLarge negative operating and free cash flow show that the business is not currently self-funding. Continued cash consumption can require additional financing, cost reductions, or stronger commercial performance, increasing execution and dilution risk over the next several quarters.
Unstable Earnings BaseThe sharp revenue decline and swing from profit to substantial loss demonstrate limited earnings stability and operating leverage. An unstable revenue base makes forecasting more difficult, raises dependence on successful product execution, and leaves less capacity to absorb setbacks in commercialization or development.
Clinical And Regulatory UncertaintyImportant pipeline opportunities remain dependent on early clinical signals becoming durable efficacy evidence and ultimately supporting regulatory progress. If later analyses weaken the current findings, expected growth catalysts could be delayed or lost, leaving greater reliance on LOQTORZI sales.
Coherus Biosciences News
8C5 FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Currently, no data Available
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is CHF137.14M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Nov 09, 2026 which is in 27 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Aug 05, 2026. The company reported -CHF0.182 earnings per share for the quarter, beating the consensus estimate of -CHF0.207 by CHF0.025.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.18.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 154,500,960 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -CHF0.182 in its last earnings report, beating expectations of -CHF0.207. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CH:8C5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.20%
12-Months-Change
Fundamentals
Return on Equity
-181.73%
Trailing 12-Months
Asset Growth
-56.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Coherus Biosciences
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
8C5 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys meaningful progress across clinical and commercial fronts: robust enrollment across multiple studies, encouraging early TAGMO signals with biomarker directionality, solid commercial momentum for LOQTORZI (+15% QoQ sales) and sustained cost/liability reductions. Offsetting risks include a sizable quarter-over-quarter cash decline (~ -36.9%), an unachieved $37.5M milestone in Q2, immature clinical datasets that could change post-data cleaning, and ongoing commercial adoption/dosing frictions. On balance, the highlights (pipeline enrollment, early efficacy signals, revenue growth, expense reductions and liability improvements) outweigh the lowlights, though near-term execution and data maturation remain critical.View all CH:8C5 earnings summaries